Chemotherapy for androgenindependent prostate cancer: Myth or reality
- 1 October 2000
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 2 (5) , 394-401
- https://doi.org/10.1007/s11912-000-0058-0
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Phase I/II Study of Gemcitabine Plus Vinorelbine as First-Line Chemotherapy of Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2000
- Combination Chemotherapy With Carboplatin, Docetaxel, and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase II StudyJournal of Clinical Oncology, 1999
- Phase II Trial of Doxorubicin and Paclitaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: An Eastern Cooperative Oncology Group StudyJournal of Clinical Oncology, 1999
- Prostate Cancer Cell Cycle Regulators: Response to Androgen Withdrawal and Development of Androgen IndependenceJNCI Journal of the National Cancer Institute, 1999
- Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients With Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III TrialJournal of Clinical Oncology, 1999
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate CancerJournal of Clinical Oncology, 1999
- PACLITAXEL(T), ESTRAMUSTINE(E) AND CARBOPLATIN(C) IN PATIENTS (Pts) WITH ADVANCED PROSTATE CANCER(PC)Journal of Urology, 1999
- Clinical Trials in Relapsed Prostate Cancer: Defining the TargetJNCI Journal of the National Cancer Institute, 1996
- Plasma Concentrations of Estramustine Phosphate and Its Major Metabolites in Patients with Prostatic Carcinoma Treated with Different Doses of Estramustine Phosphate (Estracyt®).Scandinavian Journal of Urology and Nephrology, 1981